Brief: Virios Therapeutics Gets Letter From Nasdaq, That Co Has Until Oct 30, To Regain Compliance With Minimum Bid Price Requirement
02/05/2023 22:43
May 2 (Reuters) - Virios Therapeutics Inc VIRI.O :
* VIRIOS THERAPEUTICS- GOT LETTER FROM NASDAQ STAFF, THAT CO
GRANTED ADDITIONAL 180-DAY PERIOD, OR UNTIL OCT 30, TO REGAIN
COMPLIANCE WITH MINIMUM BID PRICE REQUIREMENT
Further company coverage: VIRI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Dogwood Therapeutics
See all newsDogwood Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Dogwood Therapeutics Q2 net loss widens on higher costs, impairment charge
Brief: Dogwood Therapeutics Q2 EPS USD -0.34
Dogwood Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Dogwood Therapeutics Announces Commencement Of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2B Long Term Extension Study